Lurasidone vs Brexpiprazole — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Atypical Antipsychotic

Lurasidone

Brand: Latuda

First FDA approval: 2010-10-28

Atypical Antipsychotic

Brexpiprazole

Brand: Rexulti

First FDA approval: 2015-07-10

Lowest NADACAcquisition cost floor across all NDCs

$0.143Per unit

$49.50Per unit

Average NADACAcross all dosage forms and strengths

$3.08Up to $69.62

$49.60Up to $49.65

Generic manufacturersActive ANDA holders — FDA Orange Book

1678 total ANDAs filed

16 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$284.5MFull year

$1.37BFull year

Part D claims (CY24)Total fills, all strengths

1.3M224K beneficiaries

972K179K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$225Per claim, all NDCs

$1,408Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

250Substantial friction

750Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

5Limited friction

42Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes16 manufacturers

Yes1 manufacturers